Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome - An allostatic perspective

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 3, 2010, Pages 338-349

  Virtue, Sam ^a   Vidal Puig, Antonio ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adipose; Allostasis; Expandabillity; Insulin resistance; Lipotoxicity; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; ANTIDIABETIC AGENT; FATTY ACID; LIPID;

ADIPOCYTE; ADIPOSE TISSUE; ALLOSTASIS; ANGIOGENESIS; APOPTOSIS; BLOOD GLUCOSE MONITORING; CELL DIFFERENTIATION; DISEASE COURSE; ENERGY BALANCE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPOTHESIS; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LIPOTOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; REVIEW; TISSUE EXPANSION; TOXICITY;

ADIPOCYTES; ADIPOSE TISSUE; ALLOSTASIS; ANIMALS; CELL DIFFERENTIATION; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 76049099665     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.12.006     Document Type: Review

References (78)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 1988 (1988) 1595-1607
2. Reaven G.M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44 (1993) 121-131
3. Virtue S., and Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol. 6 (2008) e237
4. Tan C.Y., and Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem. Soc. Trans. 36 (2008) 935-940
5. Gray S.L., and Vidal-Puig A.J. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr. Rev. 65 (2007) S7-S12
6. Slawik M., and Vidal-Puig A.J. Adipose tissue expandability and the metabolic syndrome. Genes Nutr. 2 (2007) 41-45
7. Malherbe C., De Gasparo M., De Hertogh R., and Hoet J.J. Circadian variations of blood sugar and plasma insulin levels in man. Diabetologia 5 (1969) 397-404
8. Sterling P. Principles of allostasis: optimal design, predictive regulation, pathophysiology and rational therapeutics. In: Schulkin J. (Ed). Allostasis, Homeostasis, and the Costs of Adaptation (2004), Cambridge University Press
9. McEwen B.S., and Wingfield J.C. The concept of allostasis in biology and biomedicine. Horm. Behav. 43 (2003) 2-15
10. Sims E.A. Are there persons who are obese, but metabolically healthy?. Metabolism 50 (2001) 1499-1504
11. Zimmet P. Diabetes and obesity worldwide - epidemics in full flight. 60th Scientific Sessions of the American Diabetes Association, San Antonio, Texas (2000)
12. Lefterova M.I., and Lazar M.A. New developments in adipogenesis. Trends Endocrinol. Metab. 20 (2009) 107-114
13. MacDougald O.A., and Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol. Metab. 13 (2002) 5-11
14. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
15. Medina-Gomez G., Gray S.L., Yetukuri L., Shimomura K., Virtue S., Campbell M., Curtis R.K., Jimenez-Linan M., Blount M., Yeo G.S., Lopez M., Seppanen-Laakso T., Ashcroft F.M., Oresic M., and Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3 (2007) e64
16. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., Maslen G.L., Williams T.D., Lewis H., Schafer A.J., Chatterjee V.K., and O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
17. Gray S.L., Nora E.D., Grosse J., Manieri M., Stoeger T., Medina-Gomez G., Burling K., Wattler S., Russ A., Yeo G.S., Chatterjee V.K., O'Rahilly S., Voshol P.J., Cinti S., and Vidal-Puig A. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 55 (2006) 2669-2677
18. Khan T., Muise E.S., Iyengar P., Wang Z.V., Chandalia M., Abate N., Zhang B.B., Bonaldo P., Chua S., and Scherer P.E. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell Biol. 29 (2009) 1575-1591
19. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116 (2006) 3015-3025
20. Chun T.H., Hotary K.B., Sabeh F., Saltiel A.R., Allen E.D., and Weiss S.J. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125 (2006) 577-591
21. Cao Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 117 (2007) 2362-2368
22. Brakenhielm E., Cao R., Gao B., Angelin B., Cannon B., Parini P., and Cao Y. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 94 (2004) 1579-1588
23. Rupnick M.A., Panigrahy D., Zhang C.Y., Dallabrida S.M., Lowell B.B., Langer R., and Folkman M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10730-10735
24. Rodeheffer M.S., Birsoy K., and Friedman J.M. Identification of white adipocyte progenitor cells in vivo. Cell 135 (2008) 240-249
25. Tang W., Zeve D., Suh J.M., Bosnakovski D., Kyba M., Hammer R.E., Tallquist M.D., and Graff J.M. White fat progenitor cells reside in the adipose vasculature. Science 322 (2008) 583-586
26. Spalding K.L., Arner E., Westermark P.O., Bernard S., Buchholz B.A., Bergmann O., Blomqvist L., Hoffstedt J., Naslund E., Britton T., Concha H., Hassan M., Ryden M., Frisen J., and Arner P. Dynamics of fat cell turnover in humans. Nature 453 (2008) 783-787
27. Shoelson S.E., Herrero L., and Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007) 2169-2180
28. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
29. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
30. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Eagle A.R., Vats D., Brombacher F., Ferrante A.W., and Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 (2007) 1116-1120
31. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., and Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117 (2007) 1658-1669
32. Skurk T., Alberti-Huber C., Herder C., and Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 92 (2007) 1023-1033
33. Trayhurn P., Wang B., and Wood I.S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?. Br. J. Nutr. 100 (2008) 227-235
34. Pajvani U.B., Trujillo M.E., Combs T.P., Iyengar P., Jelicks L., Roth K.A., Kitsis R.N., and Scherer P.E. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11 (2005) 797-803
35. Cawthorn W.P., Heyd F., Hegyi K., and Sethi J.K. Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 14 (2007) 1361-1373
36. Shetty S., Kusminski C.M., and Scherer P.E. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci. 30 (2009) 234-239
37. Kim J.Y., van de Wall E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., Schraw T., Durand J.L., Li H., Li G., Jelicks L.A., Mehler M.F., Hui D.Y., Deshaies Y., Shulman G.I., Schwartz G.J., and Scherer P.E. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117 (2007) 2621-2637
38. Qatanani M., Szwergold N.R., Greaves D.R., Ahima R.S., and Lazar M.A. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J. Clin. Invest. 119 (2009) 531-539
39. Pedersen B.K., Akerstrom T.C., Nielsen A.R., and Fischer C.P. Role of myokines in exercise and metabolism. J. Appl. Physiol. 103 (2007) 1093-1098
40. Frayn K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 45 (2002) 1201-1210
41. Horowitz J.F., and Klein S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am. J. Physiol. Endocrinol. Metab. 278 (2000) E1144-E1152
42. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45 (2006) 42-72
43. Schenk S., Saberi M., and Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118 (2008) 2992-3002
44. Liu L., Zhang Y., Chen N., Shi X., Tsang B., and Yu Y.H. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J. Clin. Invest. 117 (2007) 1679-1689
45. Virkamaki A., Korsheninnikova E., Seppala-Lindroos A., Vehkavaara S., Goto T., Halavaara J., Hakkinen A.M., and Yki-Jarvinen H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50 (2001) 2337-2343
46. Krssak M., Falk Petersen K., Dresner A., DiPietro L., Vogel S.M., Rothman D.L., Roden M., and Shulman G.I. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42 (1999) 113-116
47. Moro C., Galgani J.E., Luu L., Pasarica M., Mairal A., Bajpeyi S., Schmitz G., Langin D., Liebisch G., and Smith S.R. Influence of gender, obesity, and muscle lipase activity on intramyocellular lipids in sedentary individuals. J. Clin. Endocrinol. Metab. 94 (2009) 3440-3447
48. Perseghin G., Scifo P., De Cobelli F., Pagliato E., Battezzati A., Arcelloni C., Vanzulli A., Testolin G., Pozza G., Del Maschio A., and Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48 (1999) 1600-1606
49. Goodpaster B.H., He J., Watkins S., and Kelley D.E. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86 (2001) 5755-5761
50. Bruce C.R., Thrush A.B., Mertz V.A., Bezaire V., Chabowski A., Heigenhauser G.J., and Dyck D.J. Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E99-E107
51. Choi C.S., Fillmore J.J., Kim J.K., Liu Z.X., Kim S., Collier E.F., Kulkarni A., Distefano A., Hwang Y.J., Kahn M., Chen Y., Yu C., Moore I.K., Reznick R.M., Higashimori T., and Shulman G.I. Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. J. Clin. Invest. 117 (2007) 1995-2003
52. Ritov V.B., Menshikova E.V., He J., Ferrell R.E., Goodpaster B.H., and Kelley D.E. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54 (2005) 8-14
53. Ukropcova B., Sereda O., de Jonge L., Bogacka I., Nguyen T., Xie H., Bray G.A., and Smith S.R. Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes 56 (2007) 720-727
54. Monetti M., Levin M.C., Watt M.J., Sajan M.P., Marmor S., Hubbard B.K., Stevens R.D., Bain J.R., Newgard C.B., Farese Sr. R.V., Hevener A.L., and Farese Jr. R.V. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6 (2007) 69-78
55. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., and Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (2007) 1366-1374
56. Bartolomucci A., Cabassi A., Govoni P., Ceresini G., Cero C., Berra D., Dadomo H., Franceschini P., Dell'Omo G., Parmigiani S., and Palanza P. Metabolic consequences and vulnerability to diet-induced obesity in male mice under chronic social stress. PLoS One 4 (2009) e4331we
57. Matsusue K., Haluzik M., Lambert G., Yim S.H., Gavrilova O., Ward J.M., Brewer Jr. B., Reitman M.L., and Gonzalez F.J. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111 (2003) 737-747
58. Kelpe C.L., Johnson L.M., and Poitout V. Increasing triglyceride synthesis inhibits glucose-induced insulin secretion in isolated rat islets of langerhans: a study using adenoviral expression of acylglycerol acyltransferase. Endocrinology 143 (2002) 3326-3332
59. Pappan K.L., Pan Z., Kwon G., Marshall C.A., Coleman T., Goldberg I.J., McDaniel M.L., and Semenkovich C.F. Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. J. Biol. Chem. 280 (2005) 9023-9029
60. Chang-Chen K.J., Mullur R., and Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord. 9 (2008) 329-343
61. Simha V., and Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr. Opin. Lipidol. 20 (2009) 300-308
62. Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S., Vottero A., Kanabar D., Charlton-Menys V., Durrington P., Soos M.A., Carpenter T.A., Lomas D.J., Cochran E.K., Gorden P., O'Rahilly S., and Savage D.B. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Invest. 119 (2009) 315-322
63. Lagathu C., Christodoulides C., Virtue S., Cawthorn W.P., Franzin C., Kimber W.A., Nora E.D., Campbell M., Medina-Gomez G., Cheyette B.N., Vidal-Puig A.J., and Sethi J.K. Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network. Diabetes 58 (2009) 609-619
64. Puri V., Ranjit S., Konda S., Nicoloro S.M., Straubhaar J., Chawla A., Chouinard M., Lin C., Burkart A., Corvera S., Perugini R.A., and Czech M.P. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7833-7838
65. Basu A., Basu R., Shah P., Vella A., Rizza R.A., and Jensen M.D. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E1000-E1006
66. Lingvay I., Esser V., Legendre J.L., Price A.L., Wertz K.M., Adams-Huet B., Zhang S., Unger R.H., and Szczepaniak L.S. Noninvasive quantification of pancreatic fat in humans. J. Clin. Endocrinol. Metab. 94 (2009) 4070-4076
67. McGavock J.M., Lingvay I., Zib I., Tillery T., Salas N., Unger R., Levine B.D., Raskin P., Victor R.G., and Szczepaniak L.S. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116 (2007) 1170-1175
68. Eyer J. Hypertension as a disease of modern society. Int. J. Health Serv. 5 (1975) 539-558
69. Kohnke M.D. Approach to the genetics of alcoholism: a review based on pathophysiology. Biochem. Pharmacol. 75 (2008) 160-177
70. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., and Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
71. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
72. Duncan G.E., Perri M.G., Theriaque D.W., Hutson A.D., Eckel R.H., and Stacpoole P.W. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 26 (2003) 557-562
73. Shu Y., Sheardown S.A., Brown C., Owen R.P., Zhang S., Castro R.A., Ianculescu A.G., Yue L., Lo J.C., Burchard E.G., Brett C.M., and Giacomini K.M. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117 (2007) 1422-1431
74. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., Brenneman A.T., Brown-Friday J.O., Goldberg R., Venditti E., and Nathan D.M. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374 (2009) 1677-1686
75. Misra A. Prevention of type 2 diabetes: the long and winding road. Lancet 374 (2009) 1655-1656
76. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., and Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8 (2008) 347-358
77. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
78. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., and Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450 (2007) 712-716